You are here

A Nano-pharmaceutical Platform for Creating Artificial Vaccines

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W911NF-11-C-0267
Agency Tracking Number: O111-H01-3056
Amount: $150,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: OSD11-H01
Solicitation Number: 2011.1
Solicitation Year: 2011
Award Year: 2011
Award Start Date (Proposal Award Date): 2011-09-26
Award End Date (Contract End Date): N/A
Small Business Information
11260 Roger Bacon Drive Suite 406
Reston, VA -
United States
DUNS: 828881305
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Steven Armentrout
 (703) 689-9689
Business Contact
 Paula Gawthorp-Armentrout
Title: Corporate Secretary
Phone: (703) 689-9689
Research Institution

In this project, Parabon NanoLabs (PNL) will demonstrate the feasibility of extending its Essemblix(tm) Drug Development Platform, a combination of computer-aided design (CAD) software and DNA nano-fabrication technology, to produce Essemblix-V, a platform for creating artificial vaccines from a predefined set of"building block molecules"assembled on DNA origami. Given an epitope for a potential biothreat agent, Essemblix-V will allow the production of artificial epitopes (hereafter"mimotopes") that can mimic the original epitope sufficiently to bind target antibodies with high affinity. Additionally, Essemblix-V will allow mimotopes to be arranged on origami in complex presentation patterns known to elicit rapid and potent immune response via T cell-independent activation. As a proof of concept, PNL will demonstrate the feasibility of (i) enhancing its existing inSequio(tm) CAD software to support the design of mimotopes with building block molecules; and (ii) modulating, through rational design, the charge distribution and hydrophobicity of specific mimotopes, since these attributes can affect conformation and stability. Prototype mimotopes will be created for /Borrelia burgdorferi/ and ricin toxin and their affinity to specific monoclonal antibodies will be demonstrated via ELISA assay. In Phase 2, artificial vaccines will be created for theses targets and evaluated in a murine model.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government